Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ALUMIS INC.

Get SEC filing alerts via email and in your feed for ALUMIS INC.

ALMS

ALUMIS INC.

About ALUMIS INC.

Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases. Its pipeline includes TYK2 inhibitors ESK-001 for psoriasis and SLE, and A-005 for neuroinflammatory conditions like MS. The company leverages proprietary data analytics and genetic insights to identify novel targets, aiming to improve patient outcomes with precision medicine. It relies on third-party manufacturing and seeks strategic collaborations for global commercialization.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from ALUMIS INC.

1
1
ALUMIS INC. Alumis Inc. Reports Fiscal Year 2025 Results with Revenue of $24.1 Million

Via official filing (AI summary) | 3 months ago | 0 comments

2
1
ALUMIS INC. Alumis Inc. Reports $294.2 Million Net Loss for 2024, Announces Merger with ACELYRIN Inc.

Via official filing (AI summary) | about 1 year ago | 0 comments